The Ministry of Science and Technology and the Commission of Health announced today (June 19) that my country's three new coronary pneumonia vaccines have made new progress and completed phase II clinical trials. It is expected that other technical route vaccines are also approved for clinical trials in the near future. Today, CCTV's "News Broadcast" column focuses on the scientific research of the new coronavirus vaccine. The following is the original text of the program:
CCTV News (News Broadcast): The Ministry of Science and Technology and the Commission of Health announced today (June 19) that five new coronavirus vaccines in my country have been approved for clinical trials, accounting for 40% of the total number of vaccines conducted in the world. It is expected that vaccines from other technical routes will also be approved for clinical trials in the near future.
my country's scientific research team has laid out 12 vaccine research and development tasks in accordance with five technical routes, including inactivated vaccine , genetic engineering recombinant subunit vaccine, adenovirus vector vaccine, attenuated influenza viral vector vaccine and nucleic acid vaccine. At present, clinical trials have been conducted on one adenovirus vector vaccine and four inactivated vaccines, accounting for 40% of the total number of vaccines conducted in the world.
From laboratory research to animal experimental research to phase one and phase two clinical trial research in humans, the scientific research team will put safety and effectiveness first, and will make unremitting efforts to provide this goal to the world to achieve application and as a public product. Experts stressed that if you face a particularly serious public health incident, in accordance with the provisions of the Vaccine Law, vaccines can be used urgently within a certain scope and time limit under the premise of full demonstration and informed consent to protect some groups with high exposure risks.
